Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board  >  Organicell Regenerative Medicine Inc       

ORGANICELL REGENERATIVE MEDICINE INC

SummaryNewsCompany 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

ORGANICELL REGENERATIVE MEDICINE : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)

share with twitter share with LinkedIn share with facebook
10/16/2020 | 08:02am EDT

The following discussion of the Company's liquidity and capital resources should be read in conjunction with our unaudited consolidated financial statements and related notes thereto appearing elsewhere herein. Unless stated otherwise, the words "we," "us," "our," the "Company" or "Organicell" in this section collectively refer to Organicell Regenerative Medicine, Inc., a Nevada corporation, and its subsidiaries.

COVID-19 Impact To Economy And Business Environment

The current outbreak of the novel coronavirus ("COVID-19") and resulting impact to the United States economic environments began to take hold during March 2020. The adverse public health developments and economic effects of the COVID-19 outbreak in the United States, have adversely affected the demand for our products and services by our customers and from patients of our customers as a result of quarantines, facility closures and social distancing measures put into effect in connection with the COVID-19 outbreak and which currently still continue to have a negative impact to our business and the economy. These restrictions have adversely affected the Company's sales, results of operations and financial condition.

There is no assurance as to when the adverse impact to the United States and worldwide economies resulting from the COVID-19 outbreak will be eliminated, if at all, and whether any new or recurring pandemic outbreaks will occur again in the future causing a similar or worse devastating impact to the United States and worldwide economies or our business.



Results of Operations


For the Three Months Ended July 31, 2019 and July 31, 2018



Revenues


Our revenues for the three months ended July 31, 2019 were $578,705, compared with revenues of $206,204 for the three months ended July 31, 2018. The increase in revenues during the three months ended July 31, 2019 of $372,501 (180.7%) was primarily the result of the Company being able to realize an increase of approximately 191.1% (approximately $379,920) in unit sales of its products during the three months ended July 31, 2019 compared with the three months ended July 31, 2018, partially offset from a decrease of approximately 3.6% (approximately $7,419) in the average sales prices for the products sold during the three months ended July 31, 2019 compared with the average sales prices realized on products sold during the three months ended July 31, 2018. The increase in the units sold was partly attributable to favorable responses to the Company's sales and marketing efforts establishing greater market awareness, less discounting of product prices to new customers, the introduction of new and more advanced product offerings and increased research and development efforts which provided customers with greater comfort in the company's products and ability to better address potential market uncertainty regarding anticipated FDA regulations.




Cost of Revenues



Our cost of revenues for the three months ended July 31, 2019 were $80,630, compared with cost of revenues of $38,971 for the three months ended July 31, 2018. The increase in cost of revenues during the three months ended July 31, 2019 compared with the three months ended July 31, 2018 was due to an increase in the amount of units sold of 191.1% (approximately $52,934) during the three months ended July 31, 2019 compared with the three months ended July 31, 2018, partially offset from the reduction in the cost of units sold of 28.9% (approximately ($11,275) during the three months ended July 31, 2019 compared to costs of units sold during the three months ended July 31, 2018, which as described above, was primarily the result of the Company manufacturing lower costing inventory for the three months ended July 31, 2019 compared with having to source its supply of inventory through third party manufacturers for the three months ended July 31, 2018 which were more costly.







  45






Gross Profit


Our gross profit for the three months ended July 31, 2019 was $498,075, compared with gross profit of $167,233 for the three months ended July 31, 2018. The increase in gross profit during the three months ended July 31, 2019 was the result of higher amount of units sold and lower the cost of units sold during the three months ended July 31, 2019 compared to the three months ended July 31, 2018. The increase in the units sold was partly attributable to favorable responses to the Company's sales and marketing efforts establishing greater market awareness and the introduction of new and more advanced product offerings. The lower cost of units sold was due to the Company once again manufacturing its products during the three months ended July 31, 2019 compared with having to source more costly supply of inventory through third party manufacturers for the three months ended July 31, 2018.

General and Administrative Expenses

General and administrative expenses for the three months ended July 31, 2019 were $837,219, compared with $468,683 for the three months ended July 31, 2018, an increase of $368,536 (78.6%). The increase in the general and administrative expenses for the three months ended July 31, 2019 was primarily the result of increased stock-based compensation costs to advisors, consultants and administrative staff during the three months ended July 31, 2019 totaling $106,011, increased payroll costs of approximately $90,000, increased commissions paid on sales of products of $68,012, increased marketing related costs of $62,639 and $48,355 of increase laboratory related expenses during the three months ended July 31, 2019 in connection with the new lab operations that began manufacturing products in May 2019.



Other Income (Expense)


Other expense, net, for the three months ended July 31, 2019 was $11,449, compared with other expense, net, of $5,838 for the three months ended July 31, 2018, an increase of $5,611. The net increase in other expense was principally the result of increased interest costs associated with outstanding debt obligations during the three months ended July 31, 2019 compared with the three months ended July 31, 2018.

For the Nine Months Ended July 31, 2019 and July 31, 2018



Revenues


Our revenues for the nine months ended July 31, 2019 were $1,116,627, compared with revenues of $716,394 for the nine months ended July 31, 2018. The increase in revenues during the nine months ended July 31, 2019 of $400,233 (55.9%) was primarily the result of the Company being able to realize an increase of approximately 53.4% (approximately $382,656) in the average sales prices for the products sold during the nine months ended July 31, 2019 compared with the average sales prices realized on products sold during the nine months ended July 31, 2018 and the Company's ability to increase unit sales of its products by 1.6% (approximately $17,577) during the nine months ended July 31, 2019 compared with the nine months ended July 31, 2018. The increase in the prices realized on product sold and units sold was partly attributable to favorable responses to the Company's sales and marketing efforts establishing greater market awareness, less discounting of product prices to new customers, the introduction of new and more advanced product offerings and increased research and development efforts which provided customers with greater comfort in the company's products and ability to better address potential market uncertainty regarding anticipated FDA regulations.




Cost of Revenues



Our cost of revenues for the nine months ended July 31, 2019 were $194,640, compared with cost of revenues of $138,271 for the nine months ended July 31, 2018. The increase in the cost of revenues during the nine months ended July 31, 2019 compared with the nine months ended July 31, 2018 was due to the increase in the cost of units sold of 38.6% (approximately $53,305) during the nine months ended July 31, 2019 compared to the cost of units sold during the nine months ended July 31, 2018, primarily the result of the Company having to source its supply of inventory through third party manufacturers for the period February 6, 2018 through April 30, 2019 which were more costly than the cost of revenues for products manufactured by the Company during the periods November 1, 2017 to February 5, 2018 and from May 1, 2019 through July 31, 2019. In addition, the increase in cost of revenues during the nine months ended July 31, 2019 compared with the nine months ended July 31, 2018 was also due to an increase of 1.6% (approximately $3,064) in the amount of units sold during the nine months ended July 31, 2019 compared with the nine months ended July 31, 2018.







  46






Gross Profit



Our gross profit for the nine months ended July 31, 2019 was $921,987, compared with gross profit of $578,123 for the nine months ended July 31, 2018. The increase in gross profit during the nine months ended July 31, 2019 of $343,864 (59.5%) was the result of the increase in the amount of units sold during the nine months ended July 31, 2019 compared to the nine months ended July 31, 2018, partially offset by higher costs of units sold during the nine months ended July 31, 2019 compared to the nine months ended July 31, 2018. The increase in the units sold was attributable to favorable responses to the Company's sales and marketing efforts establishing greater market awareness and the introduction of new and more advanced product offerings. The higher cost of units sold was due to the Company relying on more costly inventory supplied through third party manufacturers than from the Company's internally manufactured supply during certain periods during the nine months ended July 31, 2019 compared with the allocation of product supply sources for units sold during the nine months ended July 31, 2018.

General and Administrative Expenses

General and administrative expenses for the nine months ended July 31, 2019 were $1,987,737, compared with $3,649,797 for the nine months ended July 31, 2018, a decrease of $1,662,060 (45.5%). The decrease in the general and administrative expenses for the nine months ended July 31, 2019 was primarily the result of reduced stock-based compensation costs to executives during the nine months ended July 31, 2019 totaling $3,660,917, decreases in bad debt reserves of $36,090 and reduced salaries of approximately $254,000 attributable to the resignation of certain executives in connection with the Sale and Taddeo settlement, partially offset from non-recurring reductions in payroll costs totaling approximately $1,063,083 resulting from the termination and/or restructuring of executive employments agreements in connection with the Sale and the Taddeo settlement and gains realized on the sale of the Anu assets of $824,798 during the nine months ended July 31, 2018 and increased commissions paid on sales of products of $75,374, increased marketing related costs of $191,153, $54,656 of increase laboratory related expenses and $83,759 of increased professional fees and office expenses during the nine months ended July 31, 2019 compared with the nine months ended July 31, 2018.



Other Income (Expense)


Other income, net, for the nine months ended July 31, 2019 was $49,530, compared with other income, net, of $66,246 for the nine months ended July 31, 2018, a decrease of $16,716. The net decrease in the other income was the result of reduced income realized on the reduction of derivative liabilities of $265,597, partially offset by increased income from the settlement of obligations of $61,006 and reduced interest costs and amortization of discounts associated with the SPA and other interest-bearing obligations totaling $187,875.







  47





Liquidity and Capital Resources

Liquidity and Capital Resources

During the fiscal nine months ended July 31, 2019 and through the date of the filing of this Form 10-Q, the Company has relied on the sale of debt or equity securities, the restructuring of debt obligations and/or the issuance and/or exchange of equity securities to meet the shortfall in cash to fund its operations.

1. On February 5, 2019, the Company entered into an unsecured loan agreement with

    a third party with a principal balance of $25,000. The outstanding principal
    was due March 8, 2019. The loan was not repaid on the maturity date as
    required. The third party agreed to accept payment in kind consisting of
    certain products of the Company in lieu of cash interest.



2. On March 7, 2019, the Company sold an aggregate of 7,500,000 shares of common

stock and granted warrants to purchase an aggregate 2,000,000 common shares to

three "accredited investors" investors. The warrants had exercise prices of

$0.08 and had a one -year term. The aggregate grant date fair value of the

warrants issued in connection with these issuances were $6,600. The warrants

expired on March 7, 2020. The proceeds were used for working capital.

3. During March 2019, the Company issued a $30,000 of convertible 6% debentures

("30,000 Debenture") to one accredited investor. The principal amount of the

$30,000 Debenture, plus accrued and unpaid interest through June 30, 2020

were payable on the 10th business day subsequent to June 30, 2020, unless the

payment of the $30,000 Debenture was prepaid at the sole option of the

Company, or was converted as provided for under the terms of the $30,000

Debenture, and/or accelerated due to an event of default in accordance with

the terms of the $30,000 Debenture.

During June 2019, the Company and the holder of the $30,000 Debenture agreed

to convert the principal amount of the $30,000 Debentures plus interest

accrued and unpaid through the date of the conversion totaling $30,478 into

1,111,111 shares of common stock of the Company (approximately $0.0274 per

share representing a premium to the trading price of $0.0253 as of the

effective date of the transaction).

4. During April 2019, the Company sold 5,102,000 shares of common stock to seven

    "accredited investors" at $0.03 per share for an aggregate purchase price of
    $154,500. The proceeds were used for working capital.



5. During May 2019, the Company and holders of the $100,000 Debentures agreed to

    convert the principal amount of the $100,000 Debentures plus interest accrued
    and unpaid through the date of the conversion totaling $100,622 into 3,773,584
    shares of common stock of the Company (approximately $0.0267 per share
    representing a discount to the trading price of $0.0285 as of the effective
    date of the transaction).



6. On May 1, 2019, the Company, Mint Organics and the holder of a promissory note

    issued by Mint Organics agreed to a settlement of the outstanding loan whereby
    the Company agreed to issue the holder of the note 2,735,000 shares of newly
    issued common stock of the Company. At the time of the settlement, the
    outstanding obligation under the note, including late fees and penalties was
    approximately $72,568. The common stock issued was priced at $0.0265 per share
    representing a discount to the trading price of $0.049 as of the effective
    date of the transaction.



7. On May 1, 2019, the Company and Mint Organics entered into an exchange

agreement whereby the Company agreed to acquire the 150 shares of Mint Series

A Preferred Stock and the 150,000 warrants to purchase shares of common stock

of the Company originally issued to Mr. Wayne Rohrbaugh in connection with the

initial capitalization of Mint Organics (see note 15) in exchange for

4,400,000 shares of common stock of the Company (approximately $0.034 per

share representing a discount to the trading price of $0.049 as of the

effective date of the transaction).








  48





8. On May 1, 2019, the Company and Mint Organics Florida entered into an exchange

    agreement whereby the Company agreed to acquire the 21.25 units from the
    minority equity holder of Mint Organics Florida (see note 15) in exchange for
    2,400,000 shares of common stock of the Company (approximately $0.042 per
    share representing a discount to the trading price of $0.049 as of the
    effective date of the transaction).



9. During July 2019, the Company sold 2,500,000 shares of common stock to one

    "accredited investor" at $0.02 per share for an aggregate purchase price of
    $50,000. The proceeds were used for working capital.



10. During August 2019 through September 2019, the Company sold 5,250,000 shares

     of common stock to four "accredited investors" at $0.02 per share for an
     aggregate purchase price of $105,000. The proceeds were used for working
     capital.



11. On September 19, 2019, the Company's wholly owned subsidiary, General

     Surgical Florida, received $100,000 in connection with an unsecured line of
     credit ("Credit Facility"). The Credit Facility matures in one-year and the
     Company is required to make 52 weekly payments of $2,403 (payments totaling
     $125,000). The Credit Facility can be prepaid at any time by the Company. The
     effective annual interest rate of the facility based on 52 equal monthly
     payments is 45.67% Proceeds received from the Credit Facility were used for
     working capital.



12. On October 10, 2019, the Company and an investor ("Noteholder") agreed to a

      funding facility arrangement ("Funding Facility") whereby the Noteholder was
      required to fund the Company an initial tranche of $100,000 on October 15,
      2019 ("Initial Funding Date") and had the option to fund the Company up to
      an aggregate of $500,000 ("Funding Facility Limit") in minimum $100,000
      monthly tranches by no later than February 15, 2020 ("Funding Expiration
      Date"). The Funding Facility matures on February 15, 2021 ("Maturity Date")
      and accrues interest at 6.0% per annum. The Funding Facility, plus all
      accrued interest, automatically converts into 40,000,000 shares of newly
      issued common stock of the Company if the Noteholder funds the full $500,000
      by the Funding Expiration Date. The Noteholder fully funded the Funding
      Facility as prescribed on February 12, 2020 and the Company converted the
      Funding Facility into 40,000,000 shares of common stock of the Company that
      were issued to the Noteholders designated entity, Republic Asset Holdings
      LLC.

      On April 27, 2020, the Company sold 5,000,000 shares of common stock to
      Republic Asset Holdings LLC., a Company controlled by Michael Carbonara, a
      director of the Company, at $0.02 per share for an aggregate purchase price
      of $100,000. The proceeds were used for working capital.



13. During November 2019 through January 2020, the Company sold 3,250,000 shares

     of common stock to three "accredited investors" at $0.02 per share for an
     aggregate purchase price of $65,000. The proceeds were used for working
     capital.



14. During February 2020 through April 2020, the Company sold 11,050,000 shares

     of common stock to five "accredited investors" at $0.02 per share for an
     aggregate purchase price of $221,000. The proceeds were used for working
     capital.



15. During April 2020 through May 2020, the Company sold 11,000,000 shares of

     common stock to Dr. Allen Meglin, a director of the Company at $0.02 per
     share for an aggregate purchase price of $220,000. During July and August
     2020, the Company sold an additional 1,166,666 shares and 422,514 shares of
     common stock to Dr. Allen Meglin at $0.03 per share and $0.10 per share,
     respectively, for an aggregate purchase price of $77,251. The proceeds from
     all of the above sales were used for working capital.



16. During May 2020, the Company sold 3,000,000 shares of common stock to two

     "accredited investors" at $0.02 per share for an aggregate purchase price of
     $60,000. The proceeds were used for working capital.








  49

17. During July and August 2020, the Company completed the private placement to

     19 accredited investors for the sale of 13,499,992 shares of Common stock of
     the Company at a selling price of $0.03 per share for an aggregate amount of
     $405,000 ("Sale"). The proceeds are being used to fund the Company's public
     company financial reporting requirements.



18. During the period July 2020, the Company sold 1,000,000 shares of common

     stock to two "accredited investors", at $0.02 per share and $0.03 per share,
     respectively for an aggregate purchase price of $25,000. The proceeds were
     used for working capital.



19. During the period August 2020, the Company sold 8,606,665 shares of common

     stock to nine "accredited investors", at prices ranging from $0.03 per share
     and $0.06 per share, for an aggregate purchase price of $392,100. The
     proceeds were used for working capital.



20. During the period September 2020, the Company sold 4,800,000 shares of common

     stock to five "accredited investors", at prices ranging from $0.06 per share
     and $0.10 per share, for an aggregate purchase price of $410,000. The
     proceeds were used for working capital.



The Company issued the foregoing securities pursuant to the exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder.



Going Concern Consideration


The accompanying unaudited consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has had limited revenues since its inception. The Company incurred operating losses of $1,065,750 for the nine months ended July 31, 2019. In addition, the Company had an accumulated deficit of $15,563,143 at July 31, 2019. The Company had a negative working capital position of $1,452,761 at July 31, 2019.

In addition to the above, the outbreak of the novel coronavirus ("COVID-19") during March 2020 and the resulting adverse public health developments and economic effects to the United States business environments have adversely affected the demand for our products and services by our customers and from patients of our customers as a result of quarantines, facility closures and social distancing measures put into effect in connection with the COVID-19 outbreak and which currently still continue to have a negative impact to our business and the economy. These restrictions have adversely affected the Company's sales, results of operations and financial condition. In response to the COVID-19 outbreak, the Company (a) has accelerated its research and development activities, particularly in regards to potential health benefits of the Company's products in addressing various health concerns associated with COVID-19 and (b) is aggressively seeking to raise additional debt and/or equity financing to support working capital requirements until sale for its products to providers resumes to levels pre COVID-19.

As a result of the above, the Company's efforts to establish a stabilized source of sufficient revenues to cover operating costs has yet to be achieved and ultimately may prove to be unsuccessful unless (a) the United States economy resumes to pre-COVID-19 conditions and (b) additional sources of working capital through operations or debt and/or equity financings are realized. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Management anticipates that the Company will remain dependent, for the near future, on additional investment capital to fund ongoing operating expenses and the costs to perform required clinical studies in connection with the sale of its products. The Company does not have any assets to pledge for the purpose of borrowing additional capital. In addition, the Company relies on its ability to produce and sell products it manufactures that are subject to changing technology and regulations that it currently sells and distributes to its customers. The Company's current market capitalization and common stock liquidity will hinder its ability to raise equity proceeds. The Company anticipates that future sources of funding, if any, will therefore be costly and dilutive, if available at all.







  50





In view of the matters described in the preceding paragraphs, recoverability of the recorded asset amounts shown in the accompanying consolidated balance sheet assumes that (1) the effects of the COVID-19 crisis resume to pre-COVID 19 market conditions, (2) the Company will be able to establish a stabilized source of revenues, (3) obligations to the Company's creditors are not accelerated, (4) the Company's operating expenses remain at current levels and/or the Company is successful in restructuring and/or deferring ongoing obligations, (5) the Company is able to continue to produce products or obtain products under supply arrangements which are in compliance with current and future regulatory guidelines, (6) the Company is able to continue its research and development activities, particularly in regards to remaining compliant with the FDA and the safety and efficacy of its products, and (7) the Company obtains additional working capital to meet its contractual commitments and maintain the current level of Company operations through debt or equity sources.

There is no assurance as to when the adverse impact to the United States and worldwide economies resulting from the COVID-19 outbreak will be eliminated, if at all, and whether any new or recurring pandemic outbreaks will occur again in the future causing similar or worse devastating impact to the United States and worldwide economies and our business. In addition, there is no assurance that the Company will be able to complete its revenue growth strategy, its expected required research and development activities or otherwise obtain sufficient working capital to cover ongoing cash requirements. Without sufficient cash reserves, the Company's ability to pursue growth objectives will be adversely impacted. Furthermore, despite significant effort since July 2015, the Company has thus far been unsuccessful in achieving a stabilized source of revenues. As described above, the COVID-19 crisis has significantly impaired the Company and the overall Unites States and World economies. If revenues do not increase and stabilize, if the COVID-19 crisis is not satisfactorily managed and/or resolved or if additional funds cannot otherwise be raised, the Company might be required to seek other alternatives which could include the sale of assets, closure of operations and/or protection under the U.S. bankruptcy laws. As of July 31, 2019, based on the factors described above, the Company concluded that there was substantial doubt about its ability to continue to operate as a going concern for the 12 months following the issuance of these financial statements.



Cash and Cash Equivalents


The following table summarizes the sources and uses of cash for the periods stated. The Company held no cash equivalents for any of the periods presented.



                                                          For the Nine Months Ended July 31,
                                                               2019                    2018
Cash, beginning of year                                $          43,016       $          39,560
Net cash used in operating activities                           (372,568 )              (364,888 )
Net cash provided by (used in) investing activities              (32,736 )                95,453
Net cash provided by financing activities                        398,866                 250,000
Cash, end of year                                      $          36,578       $          20,125



During the nine months ended July 31, 2019, the Company used cash in operating activities of $372,568, compared to $364,888 for the nine months ended July 31, 2018, a reduction in cash used of $7,680. The change in cash used in operating activities was due to a decrease in the net loss during the nine months ended July 31, 2019 resulting from increased revenues and gross margins combined with lower general and administrative expenses after adjusting for non-cash charges (mostly related to stock based compensation, bad debt expense, settlement of executive employment obligations, reduction in derivative liabilities and the gain from the sale of the Anu assets) and liabilities owed to executive management.

During the nine months ended July 31, 2019, the Company had cash used in investing activities of ($32,736), compared to cash provided by investing activities of $95,453 for the nine months ended July 31, 2018. The increase in the change in cash used in investing activities was due primarily to increased costs associated with acquisition of fixed assets in connection with the new lab operations that commenced during May 2019 and reduced proceeds received from the sale of the Anu assets of $140,022, and reduced expenditures associated with the purchase of minority interests in Mint Organics of $40,000 that occurred during the nine months ended July 31, 2018.







  51





During the nine months ended July 31, 2019, the Company had cash provided by financing activities of $398,866, compared to cash provided by financing activities of $250,000 for the nine months ended July 31, 2018, an overall increase of $148,866. The increase in cash provided by financing activities was due to increases in proceeds from the sale of equity securities of $254,500, partially offset from decreases in proceeds received in connection with issuances of notes payable of $95,000 increased payments on capital leases of $10,634.

Off-Balance Sheet Arrangements

Our liquidity is not dependent on the use of off-balance sheet financing arrangements (as that term is defined in Item 303(a) (4) (ii) of Regulation S-K) and as of July 31, 2019 and through the date of this report, we had no such arrangements.

Recently Issued Financial Accounting Standards

In February 2016, a pronouncement was issued by the FASB that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company does not expect that implementation of the new pronouncement will have a material impact to its financial statements.



Critical Accounting Policies


Our unaudited consolidated financial statements reflect the selection and application of accounting policies which require us to make significant estimates and judgments. See Note 2 to our audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended October 31, 2018, "Summary of Significant Accounting Policies".

© Edgar Online, source Glimpses


share with twitter share with LinkedIn share with facebook
All news about ORGANICELL REGENERATIVE MEDICINE INC
10/20ORGANICELL REGENERATIVE MEDICINE, IN : Other Events, Financial Statements and Ex..
AQ
10/20ORGANICELL REGENERATIVE MEDICINE : Partners with Regenerative Care Network to St..
AQ
10/20Organicell Partners with Regenerative Care Network to Study Potential Therape..
GL
10/16ORGANICELL REGENERATIVE MEDICINE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINAN..
AQ
10/16ORGANICELL REGENERATIVE MEDICINE : Management's Discussion and Analysis of Finan..
AQ
10/16ORGANICELL REGENERATIVE MEDICINE : Management's Discussion and Analysis of Finan..
AQ
10/16ORGANICELL REGENERATIVE MEDICINE : Management's Discussion and Analysis of Finan..
AQ
09/30ORGANICELL REGENERATIVE MEDICINE, IN : Unregistered Sale of Equity Securities, C..
AQ
09/02ORGANICELL REGENERATIVE MEDICINE, IN : Other Events, Financial Statements and Ex..
AQ
08/20ORGANICELL REGENERATIVE MEDICINE, IN : Other Events (form 8-K)
AQ
More news
Managers
NameTitle
Albert Mitrani President, COO, Secretary, Treasurer & Director
Ian T. Bothwell Director, Chief Financial & Accounting Officer
Maria Ines Mitrani Director & Chief Science Officer
George Craig Shapiro Chief Medical Officer
Michael Carbonara Director
Sector and Competitors
1st jan.Capitalization (M$)
ORGANICELL REGENERATIVE MEDICINE INC0
ABBOTT LABORATORIES24.10%190 845
MEDTRONIC PLC-1.79%149 794
BECTON, DICKINSON AND COMPANY-11.65%69 650
HOYA CORPORATION14.02%42 617
BAXTER INTERNATIONAL INC.-3.03%41 050